APUS (Apimeds Pharmaceuticals US Inc.) stock: $2.67, $4.1M market cap, $0.0M cash, $4.1M EV, $44.3M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
What they do
On December 1, 2025, Apimeds Pharmaceuticals US, Inc., a Delaware corporation (“ APUS ”, the “ Company ,” “ we ,” “ us ,” or “ our ”) entered into and closed an Agreement and Plan of Merger (the “ Merger Agreement ”), with Apimeds Merger Sub, Inc., a Delaware corporation (“ Merger Sub ”), MindWave Innovations Inc, a Delaware corporation (“ MindWave ”), Lokahi Therapeutics, Inc., a Nevada corporation (“ Bio Sub ”), and Erik Emerson, solely in his capacity as representative for the Bio Business (the “ Bio Business Representative ”).
Partnerships Apimeds Inc. (Korea, related party): license and supply arrangements for APITOX in licensed territories; Piramal Pharma Solutions (manufacturing of clinical trial material)
Indications
Knee osteoarthritis (OA) - approved in South Korea since 2003; US Phase 3 planned(Approved)
Multiple sclerosis (MS) - early research(Stage not disclosed)
Status note Apitoxin approved in South Korea for OA since 2003 (MFDA). Company plans its own US Phase III in knee OA (BLA path) after the Apimeds Korea Phase III (2018) was deemed inadequate by FDA. MS efforts refocused on early-stage work. BioBusiness separation (51% Lokahi distribution) pending under April 2026 settlement.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.